15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Nanobiotix, 2 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $30.00 to $46.00, a moderate spread. The average target of $37.33 sits 2% below the current $38.26. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.00 next quarter toward $-0.29 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy267%
Hold133%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Nanobiotix.
As of Sep, 2 of 3 firms rate NBTX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
NBTX EPS & revenue forecast
EPS · NEXT QUARTER
$0.00
Range $0.00 – $0.00 · 0 analysts
Next period, 0 analysts expect Nanobiotix to earn $0.00 a share (range $0.00 – $0.00), versus — a year earlier. Full-year consensus is $-0.13, growing to $-0.29 the year after.
REVENUE · NEXT QUARTER
—
Range — – — · 0 analysts
Revenue is expected to reach — (range — – —). Full-year consensus is $38.1M, rising to $42.8M next year.
Top analysts covering Nanobiotix
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NBTX.
#1
Michael Schmidt
Guggenheim · Rank #2
Buy
$36.00-5.9% to target
Overall win rate
55%
+ Follow
#2
Jonathan Chang
Leerink Partners
Buy
$46.00+20.2% to target
Coverage
—
+ Follow
#3
DD
David Dai
UBS
Hold
$30.00-21.6% to target
Coverage
—
+ Follow
#4
CB
Colin Bristow
UBS
Hold
$30.00-21.6% to target
Coverage
—
+ Follow
#5
Tara Bancroft
TD Cowen
Buy
No targeton NBTX
Coverage
—
+ Follow
NBTX stock forecast FAQ
What is NBTX's average 12-month price target?+
The 3 analysts with a live target average $37.33 for Nanobiotix over the next 12 months, ranging from a $46.00 high to a $30.00 low.
Is NBTX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 2 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for NBTX?+
The Street-high target is $46.00 (Leerink Partners), and the Street-low is $30.00 (UBS). The average of all 3 active targets is $37.33.
How many Wall Street analysts cover NBTX?+
3 analysts have an active rating on Nanobiotix, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering NBTX?+
Among analysts who currently cover NBTX, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #2). Their current call is Buy with a $36.00 target.
What is Nanobiotix's projected EPS for next quarter?+
The consensus estimate is $0.00 per share (range $0.00 – $0.00) across 0 analysts. Full-year EPS is projected at $-0.13, rising to $-0.29 the following year.
How much revenue is Nanobiotix expected to report next quarter?+
Consensus revenue is — (range — – —). Full-year revenue is projected at $38.1M, growing to $42.8M next year.
Have analysts been upgrading or downgrading NBTX lately?+
As of Sep, 2 of 3 firms rate NBTX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NBTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
